Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBER-3
2021-000079-35Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlunestrant and abemaciclib in breast cancer (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started May 2021; status: active.
02
Drugs
imlunestrantabemaciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-000079-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000079-35.